EPIC-19 Study

Application of convalescent plasma in the treatment of COVID-19 patients with metabolomic and laboratory assessment of plasma therapy progress.


Dear Participants,

We invite you to participate in the interventional clinical trial EPIC-19, which aims to expand knowledge about the novel SARS-CoV-2 virus and develop clinical practices for the treatment of COVID-19 patients. The study aims to identify differences in serological response among COVID-19 convalescent patients with different clinical symptoms or without clinical symptoms, in order to determine the impact of different antibody levels on the effectiveness of convalescent plasma therapy in COVID-19, while also looking at the molecular perspective of study participants' plasma and identifying metabolomic markers in the blood of donors and recipients that may affect and/or condition the clinical response to the applied convalescent plasma therapy.

Login to eCRF system